Deficiency in BRCA dependent DNA inter-strand crosslink (ICL) repair is intimately connected to breast cancer susceptibility and to the rare developmental syndrome, Fanconi Anemia (FA).
INTRODUCTION
The identification of mutations within 16 different Fanconi Anemia (FA) genes has been particularly instructive regarding how specific aspects of DNA crosslink repair impact human disease phenotypes (1) (2) (3) (4) . ICL repair is initiated by a core FA protein complex, which requires monoubiquitination of the FANCD2 and FANCI proteins for localization to DNA crosslinks. ICL recognition by the canonical ubiquitinated D2-I complex is thought to direct subsequent DNA replication-dependent processing of ICLs in S-phase to DNA double-strand break (DSB) intermediates that require BRCA1 and BRCA2 for homology directed DNA repair (5, 6) . Recent evidence also implicates the BRCA proteins and Rad51 at earlier stages of ICL repair (5, 7, 8) .
The putative multifactorial involvement of individual FA genes in different aspects of ICL repair may account for the diverse spectrum of phenotypes exhibited in this syndrome. Notably, biallelic carriers of BRCA2 (FANCD1) and PALB2 (FANCN) display a severe FA phenotype and solid tumor development (9) (10) (11) , whereas this is not observed in patients with mutations in canonical FA genes.
Given the many connections between BRCA1 and both the D2-I and BRCA2-PALB2 arms of ICL repair (2, 3) , it is somewhat paradoxical that biallelic BRCA1 mutations have not been previously identified as a cause of FA. Despite high carrier frequencies in Ashkenazi Jewish populations, no patient with biallelic mutations in BRCA1 had been reported until recently (12), presumably because most combinations of deleterious BRCA1 mutations would result in embryonic lethality. This individual harbored a hypomorphic BRCA1 BRCT (BRCA1 C-terminal) repeat missense allele in trans to a frameshift mutation within BRCA1 exon 11. She presented with short stature, developmental delay, microcephaly, and ovarian cancer at age 28 with hypersensitivity to carboplatin based chemotherapy. Although this case report established that biallelic deleterious BRCA1 mutations allow viability in humans, the absence of a cell line from this patient and the lack of extensive phenotypic examination precluded definitive assessment of whether biallelic BRCA1 mutations cause FA. We report here on a second patient harboring biallelic BRCA1 mutations, early onset breast cancer, and multiple developmental and cellular anomalies consistent with a new FA subtype.
RESULTS
The proband presented at birth with microsomia and dysmorphic features ( Additional congenital abnormalities included sparse hair, upslanted palpebral fissures, blepharophimosis, a narrow palate, dental malocclusion, a high-pitched and hoarse voice, hyper and hypopigmented skin lesions, duodenal stenosis and a slightly enlarged left kidney. She has proximally inserted thumbs (Fig. 1A) , 2 nd digit camptodactyly, 2-3 toe syndactyly and hyperextensible knees as well as a history of hip dislocation. Conductive hearing loss was diagnosed at 4 years of age. Bone age at 2y 3m was delayed (1y and 6m (-2S.D.)), but had normalized by 9 years. The patient also has mild intellectual disability with significantly delayed speech. At 23 years of age she was diagnosed with ductal breast carcinoma that was estrogen and progesterone receptor positive and Her2 negative. Mastectomy was performed followed by treatment with docetaxel, fluorouracil-epirubicin-cyclophosphamide and radiation therapy. A prophylactic mastectomy was performed on the contralateral breast at age 25. The patient did not experience unusual treatment associated toxicity and has not been diagnosed with bone marrow failure to date.
Research. To identify the molecular basis for her syndromic presentation, the patient was originally within the BRCT repeats (Fig. 1B) . This missense mutation has been previously reported as a pathogenic mutation, predisposing carriers to breast and ovarian cancer (13) (14) (15) . There were no other compelling variants that explained her developmental phenotype, and none that were shared with other patients diagnosed with Dubowitz syndrome.
As BRCA1 is a major gene related to hereditary breast cancer, we performed further pedigree and genetic analysis of the family (Figs. 1B and 2A) . The proband is the second of three lymphocyte and proband skin fibroblast cultures. Upon treatment with diepoxybutane (DEB), proband lymphocytes showed increased chromosomal breakage and radial chromosome formation (30% of cells displayed radial chromosomes at 0.2 μg/mL DEB), which are well within the range established for a diagnosis of FA (Fig. 3C, 3D) (17) . Mitomycin C (MMC) treated skin fibroblast cultures from the proband also exhibited increased radial chromosomes in comparison to heterozygous sibling control fibroblasts, although quantification was not possible due to a failure to obtain sufficient numbers of proband fibroblast metaphases (Fig. 3C) . These cellular data, in concert with the clinical presentations of growth failure, microcephaly, dysmorphic faces and other congenital anomalies are supportive of a diagnosis of FA-like disorder in the proband.
BRCA1 functions in genome integrity maintenance in part through delivery of RAD51 to DSBs for homologous recombination. Consistent with impaired DSB repair function, BRCA1 and Rad51 foci were present in only 24.27 % and 26.02 % of KFB14-1 cells at 6 hours following 10
Gy IR compared to 57.14% and 65.13 % of KFB14-2 cells (Fig. 4A, B) . We next treated fibroblast cultures with MMC to test the integrity of FA-BRCA pathway function in proband cells in ICL repair. Similar to the condition of IR, MMC treated KFB14-1 cells showed less BRCA1 and Rad51 foci (30.56 % and 28.89 % respectively) compared to KFB14-2 cells (66.26 % and 62.5 % respectively) (Fig. 3B, Supplementary Fig. S1 ). To further ascertain whether mutant BRCA1 exhibited deficiency in DSB recognition, we examined localization of an epitope tagged carboxy-terminal region of BRCA1 containing the BRCT repeats to nuclease induced breaks present within a single genomic location in U2OS cells (Supplementary Fig. S2 ). The BRCA1 fragment containing p.Arg1699Trp was observed at 22. 
consistent with her less severe clinical presentation of developmental anomalies (12) and the less direct interaction of Val1736 with BRCT binding phospho-proteins (Supplementary Fig. S2 ).
BRCA mutant and other HR-deficient cells are exquisitely sensitive to PARP (poly-ADP ribose polymerase 1 and 2) inhibition (18, 19) . KFB14-1 cells were hypersensitive to the PARP inhibitor Olaparib (LC50: 2.66 µM) in comparison to KFB14-2 cells (LC50: 25.1 µM (Fig. 4C) Supplementary Fig. S3 ). These results strongly suggest defective BRCA1 dependent DNA repair in KFB14-1 cells. To verify that the pathogenic phenotype is due to the deficiency of BRCA1, we complemented the KFB14-1 cells by retroviral transduction of a cDNA expressing BRCA1 with wildtype BRCT repeats. Due to the difficulty of stable reconstitution with full length BRCA1 in primary cells, we utilized a BRCA1Δ512-1283 transgene, which has been reported to restore radiation resistance in BRCA1-BRCT mutant breast cancer cells (20) . When complemented with BRCA1Δ512-1283, KFB14-1 cells recovered Rad51 foci formation after IR or MMC exposure (Fig. 4A, B) . Furthermore, BRCA1Δ512-1283 reconstitution restored resistance in KFB-1 cells to Olaparib and to MMC (Fig. 4C, D) .
DISCUSSION
This study demonstrates that biallelic BRCA1 mutations cause a FA-like cellular and clinical phenotype in a human patient. The only other known patient with biallelic BRCA1 mutations also had a missense mutation in the BRCT repeats and presented similarly to the proband in this study with microcephaly, short stature and developmental delays. Although the chromosomal breakage test was not available, the other patient experienced significant toxicity from carboplatin, suggestive of hypersensitivity to interstrand crosslink reagents. In both cases, the The viability of biallelic BRCA1 mutations also has important implications for genetic counseling.
These two patients, together, indicate that there is a risk for couples in which each partner harbors a pathogenic BRCA1 mutation of having a child with FA-S, particularly when one of the alleles is a missense change to the BRCT repeats. On a more general note, this study demonstrates the importance of looking at all genes in a WES study, and highlights the overlap between incidental and diagnostic findings.
Biallelic BRCA2 and PALB2 mutations cause a severe FA phenotype and a distinct tumor spectrum from breast and ovarian cancer, which predominate when mutations occur in the heterozygous state (9-11). Although only two patients with biallelic mutations in BRCA1 have been reported, it is interesting to note that both maintained the breast and ovarian cancer predilection of BRCA1 carriers and neither displayed spontaneous bone marrow failure. This small sample size is suggestive of different phenotypic manifestations of biallelic BRCA1 mutations in comparison to biallelic mutations in either BRCA2 or PALB2. We posit that HR deficiency contributes to the observed phenotypes in the proband. This is based on our findings of reduced Rad51 foci formation and PARPi hypersensitivity in the proband's fibroblasts. In addition, the BRCA1 BRCT repeats are important for early stages of ICL recognition (7) . It is thus possible that multiple aspects of ICL repair function are compromised in FANCS patients and contribute to the observed phenotypes. We also acknowledge that it is possible that 
METHODS

Samples and cell lines
The patient provided written informed consent in accordance with the Declaration of Helsinki before enrollment in this study and gave additional specific approval for the publication of full facial images. The Institutional Review Board and Ethical Committee approved this study. Skin fibroblast cells KFB14-1 and KFB14-2 were derived from proband III:2 and sibling III:3, respectively. Cells were maintained in DMEM: F12 mix (Invitrogen) with 10% fetal bovine serum and pen/strep. After 3-4 times passages, Sanger sequencing was used to confirm the originally assigned BRCA1 gene sequences in the proband and sibling derived cell lines. U2OS-DSBreporter cell line was cultured in DMEM (Invitrogen) with 10% calf serum and pen/strep. Stable expression of BRCA1Δ512-1283 fibroblast cell (KB14-1) was generated by retroviral transduction.
Antibodies and chemicals
Antibodies used for protein blots and immunofluorescence are as follows: mouse monoclonal anti-BRCA1 antibody D9 (Santa Cruz Biotechnology); anti-γH2AX (Millipore); anti-Rad51 (Santa Cruz Biotechnology); anti-RPA (Novus); anti-Cyclin A (Santa Cruz Biotechnology), Olaparib (ChemieTek), MMC (Sigma).
Whole Exome sequencing and data analysis
Patient DNA was extracted from whole blood using standard protocols. DNA samples were processed by the University of Washington Center for Mendelian Genomics (UW-CMG). The initial QC entails DNA quantification, sex typing, and molecular "fingerprinting" using a 96-plex genotyping assay. Library construction (using 1 µg of genomic DNA) and exome capture are isoforms, one annotation was picked based on whether the annotation was in CCDS, the availability and value of SIFT/PolyPhen scores, and the splice site distance.
Chromosome breakage studies
The lymphocyte cultures were established from whole blood as routinely applied to make chromosomal preparations for karyotype analysis. DEB was used at a final concentration of 0.1 -0.22 μg/ml for chromosome fragility tests in lymphocytes, and 0.1μg/ml in fibroblasts.
LOH analysis
Genomic DNA was extracted from paraffin-embedded tumor samples following laser capture 
Cell survival assay
Cell survival was assessed by Cell Titer 96®Aqueous Non-Radioactive Cell Proliferation Assay kits following manufacturer instruction (promega). Experiments were repeated three times, and data represented as the mean of six replicate wells ± SEM.
Immunofluorescence
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